Patent application number | Description | Published |
20080260643 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS - A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act. | 10-23-2008 |
20080260744 | G PROTEIN COUPLED RECEPTORS AND USES THEREOF - The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels. | 10-23-2008 |
20080300240 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS - Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: | 12-04-2008 |
20090178153 | G PROTEIN COUPLED RECEPTORS AND USES THEREOF - The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels. | 07-09-2009 |
20100113486 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS - A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act. | 05-06-2010 |
20110021509 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS - Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: | 01-27-2011 |
20110091388 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS - A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act. | 04-21-2011 |
20110185439 | G PROTEIN COUPLED RECEPTORS AND USES THEREOF - The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels. | 07-28-2011 |
20110214189 | G PROTEIN COUPLED RECEPTORS AND USES THEREOF - The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels. | 09-01-2011 |
20130247233 | G PROTEIN COUPLED RECEPTORS AND USES THEREOF - The present invention provides GPCR polypeptides and polynucleotides, recombinant materials, and transgenic mice, as well as methods for their production. The polypeptides and polynucleotides are useful, for example, in methods of diagnosis and treatment of diseases and disorders. The invention also provides methods for identifying compounds (e.g., agonists or antagonists) using the GPCR polypeptides and polynucleotides of the invention, and for treating conditions associated with GPCR dysfunction with the GPCR polypeptides, polynucleotides, or identified compounds. The invention also provides diagnostic assays for detecting diseases or disorders associated with inappropriate GPCR activity or levels. | 09-19-2013 |
Patent application number | Description | Published |
20090019365 | Color calibration - Among various embodiments of the present disclosure, color calibration can be performed on a printing apparatus by using a preconfigured color map coded to reduce a color difference of a selected reference color sample relative to a color standard, where the selected reference color sample substantially matches a first test color sample printed by the printing apparatus. Installing the preconfigured color map can enable recalibrating the printing apparatus to use the preconfigured color map in adjusting an amount of a number of colorants utilized in printing a second test color sample to reduce the number of color differences of the second test color sample relative to the color standard. | 01-15-2009 |
20130004070 | Skin Color Detection And Adjustment In An Image - A preferred skin tone region is determined within a luminance-chrominance color space for each of a plurality of luminance values. Additional preferred skin tone regions are determined by interpolation in view of the initially determined preferred skin tone regions. An ellipsoid skin-color model is generated in the luminance-chrominance color space based on the preferred skin tone regions. The ellipsoid skin-color is used to detect a skin color pixel in an image and adjust one or more color values for the skin color pixel. | 01-03-2013 |
20140022570 | CONVERSION OF K-ONLY DATA FROM A SOURCE TO A DESTINATION COLOR SPACE - In an implementation, conversion of K-only data from a source CMYK color space to a destination CMYK color space is managed. The destination CMYK color space is transformed to a virtual RGB color space, in which a neutral axis of the virtual RGB color space is set to be mapped to destination K-only output colors in a color separation table for mapping of source K-only grays to destination K-only grays. The source CMYK color space is converted to a device independent color space and the conversion is adjusted such that the source K-only grays are forced to have the same chrominance as the neutral axis of the virtual RGB color space in the color separation table. The LUT is generated to include a K-only mapping by combining the virtual RGB color space with the adjusted conversion of the source K-only grays. | 01-23-2014 |
20140267197 | COLOR PERFORMANCE OF IMODS - This disclosure provides systems, methods and apparatus, including computer programs encoded on computer storage media, for making and controlling single-mirror interferometric modulators (IMODs), which may be multi-state IMODs or analog IMODs. In one aspect, a movable reflector stack or an absorber stack of an IMOD may include at least one protrusion that is configured to cause the movable reflector stack to be tilted relative to the absorber layer when the movable reflector stack is moved close to the absorber stack. The protrusion may be configured to cause color averaging when the IMOD is in a white state. The absorber stack may include an absorber layer having a lower extinction coefficient value at a red wavelength and a higher extinction coefficient value at a blue wavelength. | 09-18-2014 |
20150084980 | CONSTRAINED COLOR PALETTE FOR MULTI-PRIMARY DISPLAY DEVICES - This disclosure provides systems, methods and apparatus, including computer programs encoded on computer storage media, for displaying high bit-depth images using temporal modulation on display devices including display elements that have multiple primary colors. In order to reduce visual artifacts produced by angular metamerism, the display elements are configured to display only those combinations of the different primary colors that satisfy certain constraints. Color combinations of the multiple primary colors that satisfy these constraints are included in a constrained color palette that includes fewer than all the possible colors that can be provided by all combinations of the primary colors. | 03-26-2015 |
Patent application number | Description | Published |
20120209150 | Sub-Aperture Control in High Intensity Focused Ultrasound - Sub-aperture control is provided for high intensity focused ultrasound. Test transmissions are made sequentially from different sub-apertures. The tissue response at the focal regions is determined and used to select sub-apertures. For example, one or more sub-apertures are not used where temperature does not rise above certain threshold or tissue displacement is weak, such as associated with intervening bone or attenuating tissue. Other factors may be used instead or in addition to tissue response at the focal region. Relative proximity of the sub-apertures to a lesion, angular distribution of the sub-apertures, shape or size of the sub-aperture focal regions as compared to the tissue to be treated, or combinations thereof may be used. Once selected, the relative weight for each sub-aperture may be adjusted based on measured tissue response for each sub-aperture, such as to provide more equal treatment contribution from different sub-apertures. | 08-16-2012 |
20130296743 | Ultrasound for Therapy Control or Monitoring - Therapy control and/or monitoring is performed with an ultrasound scanner. The ultrasound scanner detects temperature to monitor therapy, and perform HIFU beam location refocusing of the therapy system based on the temperature. The monitoring is synchronized with the therapy using a trigger output of the ultrasound scanner. The trigger output responds to a scan sequence of the ultrasound scanner. To meet a given therapy plan, the scan sequence is customized, resulting in the customized trigger sequence. Three dimensional or multi-planar reconstruction rendering is used to represent temperature for monitoring feedback. The temperature at locations not being treated may be monitored. If the temperature has an undesired characteristic (e.g., too high), then the therapy is controlled by ceasing, at least temporarily. | 11-07-2013 |
20150201905 | Swept focus for acoustic radiation force impulse - Acoustic radiation force impulse (ARFI) scanning uses a swept focus in transmit. Using a changing delay or phase profile across the array during the generation of the ARFI pulse, a time varying focus is provided for the ARFI beam. This time varying focus may be used to extend the focus in depth, azimuth, and/or elevation. Less repetition may be needed to measure tissue characteristics from displacements due to the multi or continuous change in foci within a given ARFI transmit beam. | 07-23-2015 |